Direct comparison is more informative than comparing separate studies, but its result still belongs to the tested route, exposure, population, and endpoint. Primary report
What was compared
Healthy men received kisspeptin-10, kisspeptin-54, GnRH, or vehicle during separate short infusion visits, with five participants per dosing group. At the tested exposures, the kisspeptin forms produced similar gonadotropin responses, while GnRH produced larger LH and FSH responses. Primary report
Our appraisal: potency is conditional on the measurement
A hormone response during intravenous infusion is not a universal ranking of biological activity. Another route can change exposure, and another endpoint can involve additional processes. The result should not be extrapolated to nasal, oral, or subcutaneous preparations without evidence.
Matched molar administration also does not guarantee identical concentrations at every relevant target. Distribution and clearance remain part of the pharmacological comparison. A larger downstream response can reflect where the intervention acts as well as its receptor-level properties.
The word “similar” should be read carefully. A small study that does not demonstrate a difference may not be designed to establish formal equivalence. Confidence intervals, a predefined margin, and analysis plans would be needed for that stronger claim.
Finally, an acute LH or FSH response is not a fertility outcome. Full review should inspect visit order, baseline adjustment, exposure-response analysis, and safety observations. The study supports a route- and endpoint-specific physiological comparison, not general interchangeability of the two kisspeptin forms or a recommendation to choose the largest hormone response.
Frequently asked questions
Were the peptides compared directly?
Yes, under the study's infusion conditions.
Which intervention produced larger gonadotropin responses?
GnRH at the tested exposures.
Were the kisspeptin responses described as similar?
Yes.
Does that establish equivalence across all routes?
No.
Is equal molar administration identical to equal target exposure?
Not necessarily.
Was live birth the endpoint?
No.
What should accompany a potency claim?
Route, exposure, population, observation window, and measured outcome.